A Phase 3 interventional study of BGF and GFF in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 4 sites in 2 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.
Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 36th largest by enrollment, is one of 2 that started in 2019, is one of 15 in phase 3, and was the 35th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
Maria Joyera Rodríguez · Sites in Germany, Netherlands, Spain and 1 more country
Ages 40+
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 99 across the 43 interventional studies. Of the 37 that completed or were terminated, 16 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 43 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 177th largest by enrollment of the 194 interventional ones that give a count, is one of 6 that started in 2019, is one of 76 in phase 3, and was the 223rd registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing budesonide in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This is a randomised, controlled, two period cross-over, 4 weeks chronic dosing, study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) and Glycopyrronium/Formoterol Fumarate (GFF) on airway dimensions.
This is a randomised, controlled, two period cross-over, 4 weeks chronic dosing, study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF), and Glycopyrronium/Formoterol Fumarate (GFF), on specific image based airway volumes and resistance in subjects with moderate to severe Chronic Obstructive Pulmonary Disease. In this study, airway dimension parameters will be calculated for each of the active compounds.
This imaging methodology will allow an assessment of the extent of airway changes using a triple combination of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) and the dual combination Glycopyrronium/Formoterol Fumarate (GFF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must be 40 years to ≤80 years of age inclusive, at the time of signing the form at Visit 1.
Exclusion Criteria:
Spirometry Performance:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject first treated with Budesonide/Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Glycopyrronium/Formoterol Fumarate
Combination Product: BGF · Combination Product: GFF
Subject first treated with Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Budesonide/Glycopyrronium/Formoterol Fumarate
Combination Product: BGF · Combination Product: GFF
Drug pages: Budesonide · Glycopyrrolate · Formoterol
Treatment with Budesonide/Glycopyrronium/FormoterolFumarate
Treatment with Glycopyrronium/Formoterol Fumarate
Specific Image-based Airway Volume (siVaw)
Specific image-based airway volume (SiVaw) measured in mL/L. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.
Time frame: Baseline, Day 29
Specific Image-based Airway Resistance (siRaw)
Specific image-based airway resistance (siRaw) measured in kPa∙s. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.
Time frame: Baseline, Day 29
Image-based Airway Volume (iVaw)
Image-based Airway Volume (iVaw) measured in mL. Average across lobes, without adjustment for lobe volume. Reported as ratio to baseline.
Time frame: Baseline, Day 29
Image-based Airway Resistance (iRaw)
Image-based airway resistance (iRaw) measured in kPa∙s/L. Average across lobes, without adjustment for lobe volume. Reported as ratio to baseline.
Time frame: Baseline, 29 Days
Forced Expiratory Volume in One Second (Post-dose FEV1).
Change from baseline in Forced Expiratory Volume in One Second (Post-dose FEV1).
Time frame: Baseline 29 Days
Functional Residual Capacity (FRC)
Change from baseline in Functional residual capacity (FRC).
Time frame: Baseline, Day 29
This study randomized 23 subjects at 4 study centers (1 center in Belgium and 3 centers in the Netherlands) from Feb 2019 to Nov 2019.
| Milestone | BGF MDI/GFF MDI | GFF MDI/BGF MDI |
|---|---|---|
| Started | 13 | 10 |
| Completed | 13 | 9 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Milestone | BGF MDI/GFF MDI | GFF MDI/BGF MDI |
|---|---|---|
| Started | 13 | 9 |
| Completed | 13 | 9 |
| Not completed | 0 | 0 |
| Milestone | BGF MDI/GFF MDI | GFF MDI/BGF MDI |
|---|---|---|
| Started | 13 | 9 |
| Completed | 12 | 9 |
| Not completed | 1 | 0 |
| Withdrew: Severe non-compliance to protocol | 1 | 0 |
Specific image-based airway volume (SiVaw) measured in mL/L. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.
| Ratio to baseline | BGF MDI | GFF MDI |
|---|---|---|
| Specific Image-based Airway Volume (siVaw) | 1.72 (1.38 to 2.13) | 1.53 (1.28 to 1.83) |
Specific image-based airway resistance (siRaw) measured in kPa∙s. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.
| Ratio to baseline | BGF MDI | GFF MDI |
|---|---|---|
| Specific Image-based Airway Resistance (siRaw) | 0.50 (0.39 to 0.63) | 0.52 (0.40 to 0.67) |
Image-based Airway Volume (iVaw) measured in mL. Average across lobes, without adjustment for lobe volume. Reported as ratio to baseline.
| Ratio to baseline | BGF MDI | GFF MDI |
|---|---|---|
| Image-based Airway Volume (iVaw) | 1.70 (1.37 to 2.11) | 1.51 (1.26 to 1.80) |
Image-based airway resistance (iRaw) measured in kPa∙s/L. Average across lobes, without adjustment for lobe volume. Reported as ratio to baseline.
| Ratio to baseline | BGF MDI | GFF MDI |
|---|---|---|
| Image-based Airway Resistance (iRaw) | 0.50 (0.40 to 0.63) | 0.52 (0.40 to 0.68) |
Change from baseline in Forced Expiratory Volume in One Second (Post-dose FEV1).
| L | BGF MDI | GFF MDI |
|---|---|---|
| Forced Expiratory Volume in One Second (Post-dose FEV1). | 0.346 (0.182 to 0.509) | 0.273 (0.140 to 0.405) |
Change from baseline in Functional residual capacity (FRC).
| L | BGF MDI | GFF MDI |
|---|---|---|
| Functional Residual Capacity (FRC) | -0.28 (-0.77 to 0.21) | -0.50 (-0.81 to -0.18) |
Collected over Adverse events were collected from visit 2 throughout the treatment period and including the follow-up period telephone call.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BGF MDI | 0/22 (0%) | 1/22 (4.5%) | 0/22 (0%) |
| GFF MDI | 0/23 (0%) | 0/23 (0%) | 2/23 (8.7%) |
| Event | BGF MDI | GFF MDI |
|---|---|---|
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/22 | 0/23 |
| Event | BGF MDI | GFF MDI |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/22 | 2/23 |
ITT Population - all subjects who were randomized to treatment.
| Age, Continuous(Years) | Overall Study |
|---|---|
| Mean | 64.9 ± 7.6 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 5 |
| Male | 18 |
| Race (NIH/OMB)(Participants) | Overall Study |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 23 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2019 to primary completion in Nov 2019, 8 months.
Results were first posted in Feb 2021, 1 year 3 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 8 months is below that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Budesonide · Glycopyrrolate · Formoterol
Pulmonary Disease, Chronic Obstructive →